MSLN is a GPI-anchored protein bound to the cell surface that, because of its specific expression in ovarian cancer, also serves as a potential target for antigen-specific therapies as well as chimeric antigen receptor T-cell (CAR-T) therapies (41). This evidence concerns the gene MSLN and ovarian carcinoma.